U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07819474) titled 'Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With' on Sept. 10.
Brief Summary: To find out if the amount of CD8 immune cells at the place where TIL cells are collected is linked to how well a patient responds to treatment.
Study Start Date: Feb. 18, 2027
Study Type: INTERVENTIONAL
Condition:
Tumor Infiltrating Lymphocyte
CD8-PET
Advanced Melanoma
Intervention:
DRUG: Crefmirlimb
Given by Iv
DEVICE: PET/CT imaging
An additional excision, for research purposes only, will be performed from the site with the highest CD8 PET SUVmean as long as it is a dermal, ...